XTalks

JUNE 5, 2023

Semaglutide acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the GLP-1 hormone released in the gastrointestinal tract after eating. GLP-1 stimulates insulin production, thus reducing blood glucose levels, and it interacts with the brain to suppress appetite and create a feeling of fullness.

FDA Approval 91

FDA Approval Containment Drugs Pharmacy 91

XTalks

NOVEMBER 3, 2022

Mounjaro was approved this summer as a Type 2 diabetes treatment and is the first diabetes drug with dual action, targeting two hormones involved in insulin production and appetite (GIP and GLP-1). In contrast, Novo’s diabetes drugs Ozempic and Rybelsus (both semaglutide) are just GLP-1 agonists.

Sales 98

Sales FDA Approval Production Insulin 98

XTalks

FEBRUARY 21, 2024

Tirzepatide’s mechanism of action involves activating two naturally produced hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Similar to tirzepatide, dulaglutide stimulates insulin secretion, inhibits glucagon release and promotes satiety.

Clinical Trials 59

Clinical Trials Clinical Trials Trials Insulin 59

XTalks

OCTOBER 11, 2023

They mimic the action of GLP-1, a hormone that helps regulate blood sugar levels by enhancing insulin secretion. GLP-1 agonists/inhibitors work by slowing digestion to suppress appetite but can cause problems if that process slows down too much.

Drugs 59

Drugs Insulin Hormones FDA Approval 59

Roots Analysis

MARCH 21, 2022

Biologics have emerged as a direct consequence of the rapid development that has taken place in the field of life sciences, particularly in cell and molecular biology, over the past few decades. There are a variety of biologically derived therapeutics that are presently available / being developed.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Antibody Drugs 52

XTalks

APRIL 29, 2022

Tirzepatide is a novel investigational obesity treatment that contains mimetics of two hormones that are involved in regulating appetite in a single peptide: a GIP (glucose-dependent insulinotropic polypeptide) receptor agonist and a GLP-1 (glucagon-like peptide-1) receptor agonist.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

XTalks

FEBRUARY 8, 2024

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. In its 2022 financial report, Sanofi reported that sales of the long-acting insulin dropped 27.6 percent in the fourth quarter and decreased 56.7 from $289.36.

Sales 52

Sales Insulin FDA Approval Drugs 52

Roots Analysis

JANUARY 23, 2024

The peptide therapeutics market has undergone substantial evolution since the inception of insulin. They also play important roles in antibiotics , toxins, hormones, and enzymes. Presently, over 80 peptide-based drugs are available in the market for myriad of disorders and diseases.

Development 40

Development Contract Manufacturing Drugs Manufacturing 40

XTalks

SEPTEMBER 2, 2020

VK2809 is a novel, oral small molecule thyroid hormone receptor beta agonist that has selectivity for liver tissue. It is now seen as an epidemic within chronic liver disease, particularly as its prevalence has been increasing and paralleling that of obesity, making it a major health concern worldwide.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Insulin 98

XTalks

SEPTEMBER 17, 2020

Symptoms and Etiology: Caused by an overproduction of growth hormone, acromegaly primarily affects adults. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells. billion in 2022.

Sales 93

Sales Manufacturing FDA Approval Life Science 93

XTalks

MAY 20, 2022

Life science industry data analytics company Evaluate Vantage predicts that Mounjaro could bring in $4.9 The efficacy of Mounjaro was compared to placebo, Novo Nordisk’s semaglutide and two long-acting insulin analogs. percent more than placebo when used in combination with a long-acting insulin.

Insulin 52

Insulin Life Science Drugs Sales 52